

advance confirmation that prescriptions were individualised to best therapy for patients and reactive if a prescription was incorrectly written or no clarification was sought from the pharmacist during ward round. Mini-AI interviews were conducted with the pharmacists at the end of the QI project to assess their opinions on changes to the antimicrobial stewardship programme.

**Results** The chart reviews by nursing staff highlighted 98 pharmacist interventions at baseline, 275 during the intervention phase and 80 post intervention. The pharmacists recorded an extra 138, 340 and 135 baseline, during and post intervention. Proactive intervening increased during each phase 68 (49.2%), 183 (53.8%) and 84 (62.2%), respectively. Thirty eight out of the 613 (6.2%) extra interventions were not accepted, with 25 (65.7%) of these being reactive.

Gold standard prescribing improved during the intervention stage and was sustained in the post intervention phase. QI interventions brought out from the AIs involving pharmacists included RAG rating antibiotics according to priority to de-escalate to a narrower spectrum and presence at the daily microbiology round to document and communicate decisions to the wider team. AIs held with the pharmacists post project included the following themes: improved antimicrobial knowledge and understanding for directed therapy, greater communication 'as now part of the PICU microbiology team', 'increased confidence to challenge antimicrobial decisions'. The pharmacists perceive there continues to be an increase in antimicrobial discussions on the daily PICU ward round.

**Conclusion** Positive re-enforcement can improve a prescriber's antimicrobial prescribing and documentation and encourage them to proactively seek pharmacy input to ensure best directed therapy for antimicrobials. This contributes to the overall quality of antimicrobial stewardship and patient care on the unit.

## REFERENCES

1. Kelly N *et al* Learning from excellence in healthcare: a new approach to incident reporting. <http://adc.bmj.com/content/101/9/7882>
2. Plunkett A, *et al*. Positive Reporting and Appreciative Inquiry in Sepsis (PRAISE). <https://www.health.org.uk/improvement-projects/positive-reporting-and-appreciative-inquiry-in-sepsis-praise> (Accessed 13 May 2019)

P050

### ANALYSIS OF POSACONAZOLE THERAPEUTIC DRUG MONITORING IN PAEDIATRIC HAEMATOLOGY AND ONCOLOGY PATIENTS

<sup>1</sup>Natalie Donald, <sup>2</sup>Ruth Edwards, <sup>3</sup>Alison Thomson. <sup>1</sup>Royal Hospital for Children Glasgow, <sup>2</sup>Robert Gordon University; <sup>3</sup>NHS Greater Glasgow and Clyde

10.1136/archdischild-2019-nppc.59

Posaconazole is a broad spectrum triazole antifungal with activity against a range of invasive fungal pathogens including *Candida* and *Aspergillus* species.<sup>1</sup> Due to its range of activity it has been shown, by randomised controlled trials, to be superior to fluconazole and itraconazole for prevention of fungal infection in neutropenic patients,<sup>2</sup> as well as being cost saving.<sup>1</sup> Fungal prophylaxis with posaconazole has become the drug of choice within a paediatric cancer unit due to its broad spectrum of activity however there are significant differences in bioavailability of the suspension and tablet preparations and there is limited data relating to its use in the paediatric population.

**Objective** To determine if the paediatric cancer unit is undertaking effective dosing and appropriate therapeutic drug monitoring (TDM) of posaconazole in paediatric haematology and oncology patients.

**Methods** A retrospective analysis of clinical data from 38 paediatric patients treated with posaconazole was undertaken. Patients received either 18–24-mg/kg/day posaconazole suspension in divided doses (maximum 800-mg/day,<sup>3</sup> or 6–8-mg/kg/day posaconazole tablets (maximum 300-mg/day). Compliance with this guidance, initial and subsequent levels, efficacy and tolerability were analysed.

**Setting** The study was undertaken within the XXXX cancer unit; data for patients treated with posaconazole between January 2016 and August 2017 was reviewed.

**Key findings** There was good compliance with the dosing advice for liquid and tablet posaconazole with 82% of patients dosed correctly. Due to this, the initial trough level of  $\geq 0.7$  mg/L was achieved in 82% of patients within 14 days of treatment initiation; there were no significant differences between formulations. Trough levels were monitored on a monthly basis for 71% of patients but dose adjustments were necessary in 34% of patients. Posaconazole had a good tolerability profile during the study with most side effects resolving on continuation of treatment however one patient had to discontinue the drug due to widespread rash. No patients developed a fungal infection whilst on posaconazole.

**Conclusion** Safe and effective dosing and monitoring of posaconazole suspension and tablet formulations has been undertaken at the XXXX. Trough levels attained the desired target concentration of  $\geq 0.7$  mg/L in the majority of patients but dose adjustments were required with both formulations emphasising the need for regular TDM. Posaconazole was well tolerated and clinically effective in preventing fungal infection indicating its appropriateness in this patient group. From this review, a guideline for initiation and appropriate TDM of posaconazole can be developed.

## REFERENCES

1. Dranitsaris G, Khoury H. Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. *Supportive Care in Cancer*. 2011; **19**(11): 1807–1813.
2. Cornely O, Maertens J, Winston D, *et al*. Posaconazole vs. Fluconazole or Itraconazole in Patients with Neutropenia. *New England Journal of Medicine*. 2007; **356**(4): 348–359.
3. Bernardo V, Cross S, Crews K, *et al*. Posaconazole Therapeutic Drug Monitoring in Paediatric Patients and Young Adults with Cancer. *The Annals of Pharmacotherapy*. 2013; **47**: 976–983.

P051

### THE BIGGER YOU ARE THE HARDER YOU FALL? SHORT TERM EFFECTS OF LUM/IVA (ORKAMBI) ON LUNG FUNCTION IN CHILDREN WITH CYSTIC FIBROSIS

Emma O' Grady, Rebecca Finnegan, Anna Smyth, Stephanie Ryan, Michael Williamson. Temple Street Children's University Hospital, Dublin

10.1136/archdischild-2019-nppc.60

**Aim** Cystic Fibrosis conductance Transmembrane Regulator (CFTR) protein modulators represent a major breakthrough in the pharmacological management of Cystic Fibrosis (CF). Previous studies report acute changes in lung function after first administration of lumacaftor/ivacaftor (LUM/IVA) without a clear underlying mechanism.<sup>1 2</sup> Our aim was to explore links between changes in percent predicted forced expiratory